A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes

Santiwarangkool, Sarochin; Akita, Hidetaka; Khalil, Ikramy A.; Elwakil, Mahmoud M. Abd; Sato, Yusuke; Kusumoto, Kenji; Harashima, Hideyoshi

doi:10.1016/j.jconrel.2019.06.009

Cited by 35 publications

(23 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, liposomes decorated with fusogenic peptides and lipids such as the zwitterionic lipid dioleoylphosphatidylethanolamine can follow lipid-rafts mediated endocytosis related to CVME as described for human hepatocyte carcinoma Hep G2 and human malignant melanoma A375 cells [62]. However, other modifications do not seem to change the CME pathway that liposomes usually follow, as it happens with GALA peptide (WEAALAEALAEALAEHLAEALAEALEALAA)-modified liposomes in human lung microvascular endothelial cells (HMVEC-L) [63] or liposomes containing a malachite green derivative in the lipid membrane [64] in mouse colon adenocarcinoma Colon 26 cells. Nevertheless, the entrance of lipid modified liposomes depends also on the cell type, being this the case for exosome-mimicking liposomes that were formulated with DOPC/SM/Chol/DOPS/DOPE, where the uptake is dependent on CVME and macropinocytosis in A549 cells, while for human umbilical vein endothelial cells (HUVEC) it depends on CME [65].…”

Section: Liposomesmentioning

confidence: 99%

Endocytosis: The Nanoparticle and Submicron Nanocompounds Gateway into the Cell

2020

View full text Add to dashboard Cite

Nanoparticles (NPs) and submicron particles are increasingly used as carriers for delivering therapeutic compounds to cells. Their entry into the cell represents the initial step in this delivery process, being most of the nanoparticles taken up by endocytosis, although other mechanisms can contribute to the uptake. To increase the delivery efficiency of therapeutic compounds by NPs and submicron particles is very relevant to understand the mechanisms involved in the uptake process. This review covers the proposed pathways involved in the cellular uptake of different NPs and submicron particles types as well as the role that some of the physicochemical nanoparticle characteristics play in the uptake pathway preferentially used by the nanoparticles to gain access and deliver their cargo inside the cell.

show abstract

Section: Liposomesmentioning

confidence: 99%

Endocytosis: The Nanoparticle and Submicron Nanocompounds Gateway into the Cell

2020

View full text Add to dashboard Cite

show abstract

“…[ 34 ] However, a recent report suggests that clathrin‐mediated endocytosis may also facilitate transcytosis of nanoparticles, as demonstrated with GALA peptide‐functionalized liposomes. [ 36 ] Additionally, many other clathrin‐ and caveolae‐independent (CCI) pathways exist and have been extensively researched. These processes have been shown to take up cargoes such as folate, folate‐modified materials, [ 24 ] extracellular fluids, interleukin‐2, S40 virions, growth hormone, and endothelin [ 37 ] in several cell lines possessing a high membrane lipid content but neither clathrin nor caveolae receptors.…”

Section: Cellular Uptake Mechanism For Nanoparticlesmentioning

confidence: 99%

Nanocarrier‐Mediated Cytosolic Delivery of Biopharmaceuticals

Xing

Wang

et al. 2020

Adv Funct Materials

125

View full text Add to dashboard Cite

Biopharmaceuticals have emerged to play a vital role in disease treatment and have shown promise in the rapidly expanding pharmaceutical market due to their high specificity and potency. However, the delivery of these biologics is hindered by various physiological barriers, owing primarily to the poor cell membrane permeability, low stability, and increased size of biologic agents. Since many biological drugs are intended to function by interacting with intracellular targets, their delivery to intracellular targets is of high relevance. In this review, the authors summarize and discuss the use of nanocarriers for intracellular delivery of biopharmaceuticals via endosomal escape and, especially, the routes of direct cytosolic delivery by means including the caveolae‐mediated pathway, contact release, intermembrane transfer, membrane fusion, direct translocation, and membrane disruption. Strategies with high potential for translation are highlighted. Finally, the authors conclude with the clinical translation of promising carriers and future perspectives.

show abstract

“…126) The activity was further improved by using the ethanol dilution method of preparation and by adding a vitamin E-scaffold SS-cleavable pH-activated lipid-like material (ssPalmE), which improved the endosomal escape of siRNA (ED 50 value = 0.21 mg siRNA/kg). 127) Further improvement in the endosomal escape through using an ionizable lipid, YSK05, significantly improved the gene silencing activity in the lung endothelium (ED 50 value = 0.01 mg siRNA/kg). 50) Although the use of YSK05 dramatically improved the activity by approx.…”

Section: Gene Delivery To the Lung Endothelium The Lungmentioning

confidence: 99%

Lipid Nanoparticles for Cell-Specific <i>in Vivo</i> Targeted Delivery of Nucleic Acids

Khalil

Younis

Kimura

et al. 2020

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

The last few years have witnessed a great advance in the development of nonviral systems for in vivo targeted delivery of nucleic acids. Lipid nanoparticles (LNPs) are the most promising carriers for producing clinically approved products in the future. Compared with other systems used for nonviral gene delivery, LNPs provide several advantages including higher stability, low toxicity, and greater efficiency. Additionally, systems based on LNPs can be modified with ligands and devices for controlled biodistribution and internalization into specific cells. Efforts are ongoing to improve the efficiency of lipid-based gene vectors. These efforts depend on the appropriate design of nanocarriers as well as the development of new lipids with improved gene delivery ability. Several ionizable lipids have recently been developed and have shown dramatically improved efficiency. However, enhancing the ability of nanocarriers to target specific cells in the body remains the most difficult challenge. Systemically administered LNPs can access organs in which the capillaries are characterized by the presence of fenestrations, such as the liver and spleen. The liver has received the most attention to date, although targeted delivery to the spleen has recently emerged as a promising tool for modulating the immune system. In this review, we discuss recent advances in the use of LNPs for cellspecific targeted delivery of nucleic acids. We focus mainly on targeting liver hepatocytes and spleen immune cells as excellent targets for gene therapy. We also discuss the potential of endothelial cells as an alternate approach for targeting organs with a continuous endothelium.

show abstract

A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes

Cited by 35 publications

References 41 publications

Endocytosis: The Nanoparticle and Submicron Nanocompounds Gateway into the Cell

Endocytosis: The Nanoparticle and Submicron Nanocompounds Gateway into the Cell

Nanocarrier‐Mediated Cytosolic Delivery of Biopharmaceuticals

Lipid Nanoparticles for Cell-Specific <i>in Vivo</i> Targeted Delivery of Nucleic Acids

Contact Info

Product

Resources

About